Biomarkers in schizophrenia
Precompetitive consortium approach to validation of the next generation of biomarkers in schizophrenia
Using biomarkers to inform diagnosis, guide treatments and track response to interventions in psychotic illnesses
Serum levels of the soluble IL-1 receptor family member ST2 and right ventricular dysfunction
The use of proteomic biomarkers for improved diagnosis and stratification of schizophrenia patients
Use of translational pharmacodynamic biomarkers in early-phase clinical studies for schizophrenia
Biomarkers in psychosis: an approach to early identification and individualized treatment
Unresolved questions in Alzheimer's research: will biomarkers help?
Biomarkers for fatal immune response to stem cell treatment could reduce mortality
Can a new breath test help detect lung cancer?
mRNA biomarker may lead to earlier diagnosis of pancreatic cancer
Mitochondrial DNA identified as a key player in breast cancer metastasis
A genetic biomarker for colorectal cancer could reduce the need for invasive testing
Trust your gut: a gastric hormone may predict the efficacy of gastric bypass
An IL-17-mediated paracrine network promotes tumor resistance to antiangiogenic therapy
How to link biomarkers using physiologically based pharmacokinetic models
A new biomarker to identify high-risk renal transplant patients
Predicting the chance of relapse after tamoxifen treatment in breast cancer
Current and future roles of biochemical biomarkers in hypertrophic cardiomyopathy
Urinary biomarkers track the progression of nephropathy in hypertensive and obese rats
Resistin as a biomarker linking obesity and inflammation to cancer: potential clinical perspectives
Advances in technologies for screening and diagnosis of hemoglobinopathies
Chromogranin A as a biomarker in cardiovascular disease